Contact Pfizer Media Relations
This information is intended for media professionals.
This information is intended for media professionals only. To ensure that customers, investors, and others receive the appropriate attention, Pfizer media contacts may ONLY respond to calls and emails from professional journalists.
If you are not a journalist, please visit the Contact Page and consult the appropriate Pfizer contact.
Phone: (212) 573-1226
For specific media inquiries:
Europe/Africa/Middle East, email wwce@pfizer.com
You can also visit our Pfizer Worldwide Web Sites.
| Contact |
Responsibility |
Key Focus Areas/Issues (Not all-inclusive) |
|---|---|---|
| Ray Kerins W: 212-733-9203 C: 917-324-0080 Ray.Kerins@pfizer.com |
Vice President, Head of Media Relations and Public Relations | |
| Chris Loder W: 212-733-7897 C: 347-453-8199 Christopher.Loder@pfizer.com |
Head of Media Relations - United States | Litigation; Counterfeiting; Specialty Care; Oncology |
| Sally Beatty W: 212-733-6566 C: 347-330-7867 Sally.Beatty@pfizer.com |
Primary Care Brands | Apixaban, Celebrex, Chantix, Lipitor, Lyrica, Viagra |
| Rick Chambers W: 269-833-6387 C:269-760-0770 Richard.T.Chambers@pfizer.com |
Global Manufacturing; Global Engineering; U.S. Regional Support | Environmental; Manufacturing sites |
| Kristen Neese W: 212-733-8926 C: 646-299-2526 Kristen.E.Neese@pfizer.com |
Policy; PGRD | Medical and Science Communications |
| Liz Power W: 860-732-4987 C: 860-501-3849 Elizabeth.Power@pfizer.com |
PGRD (New London/Groton) | Medical and Science Communications |
| Joan Campion W: 212-733-2798 C: 201-761-9384 Joan.Campion@pfizer.com |
Finance; Earnings/SEC Filings; Corporate Governance; Business Development | Finance; Business Development |
| Samantha Cummis W: 212-733-6924 C: 917-679-8413 Samantha.Cummis@pfizer.com |
Business Development | |
| Oliver Stohlmann W: 43 1 52115 337 C: 43 664 3350485 Oliver.Stohlmann@pfizer.com |
Head of European Corporate Communications | Litigation; Counterfeiting; Specialty Care; Oncology |
| Andrew Topen W: 44 1737 332236 C: 44 7967 757688 Andrew.Topen@pfizer.com |
Head of European Primary Care Communications | |
| Monica Pinuela W: 34 91 490 99 20 C: 34 647 37 62 85 Monica.Pinuela@pfizer.com |
Europe | R&D/science; Product Communications |
| Shreya Jani W: 212-733-4889 C: 917-743-4349 Shreya.Jani@pfizer.com |
Head of Media Relations - Asia, Africa, Middle East, Latin America | Emerging Markets; Established Products; Philanthropy |
| Tyrene Frederick-Mack W: 212-733-3848 C: 917-327-7821 Tyrene.Frederick-Mack@pfizer.com |
Latin America | |
| Marco Winkler W: 212-733-9313 C: 646-318-1264 Marco.Winkler@pfizer.com |
Eastern Europe, Middle East, Africa | |
| Neena Moorjani W: 852 2287 9939 C: 852 9038 0150 Neena.Moorjani@pfizer.com |
Asia Pacific | |
| Rick Goulart W: 212-733-7457 C: 860-501-3391 Rick.Goulart@pfizer.com |
Animal Health |
Stock Quote Disclaimer
20 minute delayed data provided by Comstock. Charts are provided by BigCharts and MarketWatch, Inc. Pfizer makes no claims concerning the accuracy of the information provided on these pages, and will not be held liable for any use of this information. Note: Historical and current stock price performance data is not necessarily indicative of future performance.
Stock Symbol: PFE Stock Exchange: NYSE
Stock Quote at: Nov 20 2009 4:00PM
| Last 18.36 | Change 0.25 |
| %Change | 1.38 | Vol. | 60,966,550 |
| Day High | 18.48 | 52 Wk. High | 18.48 |
| Day Low | 18.12 | 52 Wk. Low | 11.62 |
| Open | 18.15 | Mkt. Cap(Bil) | 148.16 |
| Prev. Close | 18.11 |
Pfizer Annual Review:
Doing Things Differently
We are becoming the Pfizer we are meant to be — one that can offer healthy solutions at every stage of life.